A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

Part of paid clinical trials in Chula Vista, California.

Sponsor
Carmot Therapeutics, Inc.
Study ID
NCT05794581
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • CT-868 — DRUG
    CT-868
  • Placebo — DRUG
    Placebo as SC Injection
  • Victoza — DRUG
    Victoza as active comparator as SC Injection

Study Details

This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.

Key Dates

Start date
Mar 21, 2023
Status verified
Dec 2024
Primary completion
Mar 6, 2024
Completion
Apr 6, 2024

Study Design

Enrollment
32 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: CT-868
    SC injection of CT-868 Intervention
  • Placebo Comparator: Placebo
    SC injection of placebo matching CT-868 dose
  • Active Comparator: Victoza
    SC injection of active comparator

Primary Outcome Measure

To assess area under the curve (AUC) in glucose metabolism during MMTT [ Time Frame: Baseline up to 4 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Carmot Clinical Research Unit 101Chula VistaCalifornia91911-

Find similar trials in Chula Vista, CA

By condition
Type 1 diabetes
By specialty
Endocrinology
By research site
Carmot Clinical Research Unit 101· Chula Vista, CA

Related Studies